Under the agreement, Medsintez will transfer advanced biological drug manufacturing technology to VNVC, collaborate in R&D and clinical trials of new drugs and vaccines, and distribute high-quality Medsintez products in Viet Nam and ASEAN countries.
In the near future, numerous advanced biological drugs including recombinant Albumin and Insulin, single-use and reusable insulin pens, diabetes medicines such as liraglutide and semaglutide, the anticoagulant Heparin, the antiviral Triazavirin, and follicle-stimulating hormone for infertility treatment. These will be produced by VNVC under international standards.
The two sides will also cooperate to clinically research the antiviral Triazavirin for treating dengue fever, a serious disease in Viet Nam.
Speaking at the signing ceremony, Russian Health Minister Mikhail Murashko highlighted that the cooperation aims to benefit public health and improve healthcare quality.
For her part, Vietnamese Health Minister Dao Hong Lan thanked Russia for decades-long support in training doctors, supplying medicines, vaccines, and modern medical technologies.
The cooperation opens practical partnerships between research institutes and high-tech medical centres of both countries, especially in advanced cancer treatment and the production of crucial medicines and vaccines.
By the end of 2027, VNVC factory plans to start producing new generation vaccines and advanced biological drugs in Viet Nam for multiple countries, reaffirming the long-term significance of this cooperation.
